• Explore /
  • Poster
  • / ARC-8: Phase 1/1b randomized study of quemliclustat + gemcitabine/nab-paclitaxel ± zimberelimab in patients with treatment-naive metastatic pancreatic adenocarcinoma.

ARC-8: Phase 1/1b randomized study of quemliclustat + gemcitabine/nab-paclitaxel ± zimberelimab in patients with treatment-naive metastatic pancreatic adenocarcinoma.

Abstract Poster

Authors

null

Zev A. Wainberg

David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA

Zev A. Wainberg , Gulam Abbas Manji , Nathan Bahary , Susanna Varkey Ulahannan , Shubham Pant , Nataliya Volodymyrivna Uboha , Paul Eliezer Oberstein , Lawrence H Lu , Jennifer R. Scott , Wilson Wu , Joon Rhee , Dimitry S. A. Nuyten , Eileen Mary O'Reilly

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04104672

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr 665)

DOI

10.1200/JCO.2024.42.3_suppl.665

Abstract #

665

Poster Bd #

L14

Abstract Disclosures

Similar Posters

First Author: Gulam Abbas Manji

Poster

2023 ASCO Gastrointestinal Cancers Symposium

Metronomic oral cyclophosphamide as maintenance therapy in metastatic pancreatic ductal adenocarcinoma.

Metronomic oral cyclophosphamide as maintenance therapy in metastatic pancreatic ductal adenocarcinoma.

First Author: Michele Reni

First Author: Johanna C. Bendell

First Author: Philippa Corrie